Nuvo Pharmaceuticals Inc banner

Nuvo Pharmaceuticals Inc
TSX:MRV

Watchlist Manager
Nuvo Pharmaceuticals Inc Logo
Nuvo Pharmaceuticals Inc
TSX:MRV
Watchlist
Price: 1.35 CAD Market Closed
Market Cap: CA$15.4m

Wall Street
Price Targets

MRV Price Targets Summary
Nuvo Pharmaceuticals Inc

There are no price targets for MRV.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Nuvo Pharmaceuticals Inc Competitors:
Price Targets
CCOI
Cogent Communications Holdings Inc
20% Upside
M3C0
Mitsubishi Chemical Group Corp
-16% Downside

Revenue
Forecast

18% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
18% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

For the last 8 years the compound annual growth rate for Nuvo Pharmaceuticals Inc's revenue is 18%. The projected CAGR for the next 2 years is 5%.

Operating Income
Forecast

N/A
Past Growth
-26% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
-26% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Nuvo Pharmaceuticals Inc's operating income for the next 4 years is -26%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-28%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-28%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MRV's stock price target?
Not Available

MRV doesn't have any price targets made by Wall Street professionals.

What is Nuvo Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
5%

For the last 8 years the compound annual growth rate for Nuvo Pharmaceuticals Inc's revenue is 18%. The projected CAGR for the next 2 years is 5%.

What is Nuvo Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
-26%

The compound annual growth rate of Nuvo Pharmaceuticals Inc's operating income for the next 4 years is -26%.

Back to Top